RxDoctor Payments Data

Ka Lok Tse, MD

Nephrology · Pasadena, CANPI 1093730491

Payments from drug & device makers

$51,618in general payments, 2019–2025

Across 337 payments — averaging $153.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$32K
  • Fresenius USA Marketing, Inc.$14K
  • Aurinia Pharma U.S., Inc.$691
  • GSK$659
  • Mallinckrodt Hospital Products Inc.$626
  • Amgen$612
  • plus $3K from 20 others

What the payments were for

  • Speaking & faculty fees$39,75077%
  • Travel & lodging$2,6345%
  • Food & beverage$9,03217%
  • Education$2020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,618 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$238,479
Medicare patients
409
Services billed
1,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol633$465,592
JardianceEmpagliflozin299$319,118
KerendiaFinerenone239$245,121
JynarqueTolvaptan11$210,342
XphozahTenapanor Hcl31$109,288
LokelmaSodium Zirconium Cyclosilicate83$101,981
VelphoroSucroferric Oxyhydroxide39$87,923
VeltassaPatiromer Calcium Sorbitex47$71,343
ProcritEpoetin Alfa78$60,656
ProsolParenteral Amino Acid 20% No.1328$46,114
EntrestoSacubitril/Valsartan29$25,559
EliquisApixaban21$18,021
Cinacalcet Hcl38$18,016
Sevelamer Carbonate60$17,767
RetacritEpoetin Alfa-Epbx31$11,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$32,085$567,572716 claims
Boehringer IngelheimJardiance$187$319,118299 claims
BayerKerendia$495$245,121239 claims
Otsuka America Pharmaceutical, Inc.Jynarque$523$210,34211 claims
Fresenius USA Marketing, Inc.Velphoro$13,564$87,92339 claims
NovartisEntresto$297$25,55929 claims
ANI Pharmaceuticals, Inc.Valsartan$149$1,28143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →